{"filing":{"accession_number":"0001493152-26-033289","cik":"0001962011","ticker":"KAPA","company_name":"Kairos Pharma, LTD.","form":"8-K","filing_date":"2026-07-15","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1962011/000149315226033289/form8-k.htm"},"events":[{"id":18029,"run_id":16184,"accession_number":"0001493152-26-033289","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Kairos Pharma disclosed interim safety data from an ongoing Phase 1 clinical trial of ENV-105 (Carotuximab) in combination with osimertinib for EGFR-mutated lung cancer. The press release highlights a \"clean safety profile\" with zero Grade 3+ toxicities in 13 patients, representing a material clinical milestone for the company's lead program. This is a clinical development milestone—a key operational and strategic event for a clinical-stage biopharmaceutical company—rather than a financial result, M\u0026A activity, or governance matter. While clinical trial data disclosures are common for biotech firms, the characterization as \"breakthrough\" interim safety data and the emphasis on advancing toward efficacy readout make this material to investors assessing the registrant's pipeline progress and value.","company_name":"Kairos Pharma, LTD.","ticker":"KAPA","filing_date":"2026-07-15","form":"8-K","submitted_at":null,"items":[{"id":16722,"accession_number":"0001493152-26-033289","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Kairos Pharma disclosed interim safety data from an ongoing Phase 1 clinical trial of ENV-105 (Carotuximab) in combination with osimertinib for EGFR-mutated lung cancer. The press release highlights a \"clean safety profile\" with zero Grade 3+ toxicities in 13 patients, representing a material clinical milestone for the company's lead program. This is a clinical development milestone—a key operational and strategic event for a clinical-stage biopharmaceutical company—rather than a financial result, M\u0026A activity, or governance matter. While clinical trial data disclosures are common for biotech firms, the characterization as \"breakthrough\" interim safety data and the emphasis on advancing toward efficacy readout make this material to investors assessing the registrant's pipeline progress and value.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T12:31:43.537691+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16722,"accession_number":"0001493152-26-033289","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Kairos Pharma disclosed interim safety data from an ongoing Phase 1 clinical trial of ENV-105 (Carotuximab) in combination with osimertinib for EGFR-mutated lung cancer. The press release highlights a \"clean safety profile\" with zero Grade 3+ toxicities in 13 patients, representing a material clinical milestone for the company's lead program. This is a clinical development milestone—a key operational and strategic event for a clinical-stage biopharmaceutical company—rather than a financial result, M\u0026A activity, or governance matter. While clinical trial data disclosures are common for biotech firms, the characterization as \"breakthrough\" interim safety data and the emphasis on advancing toward efficacy readout make this material to investors assessing the registrant's pipeline progress and value.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T12:31:43.537691+00:00","company_name":"Kairos Pharma, LTD.","ticker":"KAPA","filing_date":"2026-07-15"}]}